Fundraising Fox
/Companies
Sign in

Aer Therapeutics

Raleigh, US · Founded 2014 · 10 employees on LinkedIn · 4 known investors

Find your way into Aer Therapeutics

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma. The company focuses on respiratory care for patients with these conditions.

BiotechHealthtechMedical Devices

Founders & leadership

TMThomas Mathers
Thomas MathersExecutive Chairman of the Board of Directors
JS
James ShafferExecutive
JFJohn Fahy
John FahyFounder and Chief Clinical Consultant

Board

CSChristy Shaffer
Christy ShafferBoard directorChristy Shaffer, a director at Aer Therapeutics, has over 30 years of experience in the biopharma industry and works at Hatteras Venture Partners in Durham, NC. She has served on 12 corporate boards, including three public company boards, as well as disease foundation boards.
RG
Rishi GuptaBoard directorPartner at OrbiMed
TSTim Shannon
Tim ShannonBoard directorGeneral Partner at Canaan Partners
ECEvan Caplan
Evan CaplanBoard directorPartner at OrbiMed

Investors · 4

OrbiMed✓ confirmed by Aer TherapeuticsNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham

How we know: Pappas Capital's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$23.9M disclosed across 3 rounds · 2022–2026

▶$3MraisedAug 2026 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas MathersExecutive Officer, Director
  • John FahyDirector
  • Evan CaplanDirector
  • Tim ShannonDirector
  • Christy ShafferDirector
Offering amount
$3M
Amount sold
$3M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedFeb 2025 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CHRISTY SHAFFERDirector
  • THOMAS MATHERSExecutive Officer, Director
  • RISHI GUPTADirector
  • JOHN FAHYDirector
  • TIM SHANNONDirector
Offering amount
$5M
Amount sold
$5M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.9MraisedDec 2022 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tim ShannonDirector
  • Christy ShafferDirector
  • Rishi GuptaDirector
  • James ShafferExecutive Officer, Director
  • John FahyDirector
Offering amount
$36.9M
Amount sold
$15.9M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Investors - AER Therapeuticsaertherapeutics.com · May 2025Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases - AER Therapeuticsaertherapeutics.com · Apr 2023

Frequently asked questions

What does Aer Therapeutics do?
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma. The company focuses on respiratory care for patients with these conditions.
Who are Aer Therapeutics's investors?
Aer Therapeutics's investors include Hatteras Venture Partners, OrbiMed, Canaan Partners, Pappas Capital.
How much funding has Aer Therapeutics raised?
Aer Therapeutics has disclosed $23.9M raised across 3 rounds.
Where is Aer Therapeutics headquartered?
Aer Therapeutics is headquartered in Raleigh, US.